<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581242</url>
  </required_header>
  <id_info>
    <org_study_id>BKP-1003</org_study_id>
    <nct_id>NCT01581242</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects</brief_title>
  <acronym>BKP-1003-101</acronym>
  <official_title>A Randomized, Open-label, Three-sequence, Three-period, Three-treatment Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, three-sequence, three-period, three-treatment clinical
      trial to investigate the pharmacokinetic drug-drug interaction of Clevudin and Adefovir
      dipivoxil after oral administration in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety, drug-tolerance, pharmacokinetics of Clevudine or Adefovir monotherapy
      or Adefovir and Clevudine combination in healthy male subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Predose ~24hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Predose~24hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Predose~24hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Predose~24hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Predose~24hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Predose~24hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Screening, predose, post 24h, Post-study visit</time_frame>
    <description>clinically measured adverse events, abnormality of laboratory tests abnormality of vital signs,ECG e.t.c</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil</intervention_name>
    <description>Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil</intervention_name>
    <description>Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil</intervention_name>
    <description>Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age limit is from 20 to 45 with healthy male subjects in screening

          -  Weight limit is from 50kg(110.23Ib) to 90kg(198.41Ib) with BMI 18.5-26 (BMI(kg/m2)=
             weight(kg)/{height(m)}2

          -  The person who fully understands and listens about this clinical trial, receives
             written consent to observe the notandum and decides to participate voluntarily

        Exclusion Criteria:

          -  The person who has past history or serious disease in liver, kidney, nervous system,
             respiratory system, gastro-intestinal tract system, endocrine system, blood tumor,
             cardio-vascular system, urinary system, mental system clinically

          -  The person who has the past history of Gastro-intestinal operation(except simple
             appendectomy or herniotomy)or Gastro-intestinal system disease (Chron's
             disease,ulcer,acute and chronic pancreatitis, etc) that can be influenced the
             absorption of clinical drug

          -  The person who has the past history of hypersensitivity reaction about the drugs that
             contain the identical affiliation ingredient or ingredient of Clevudine, Adefovir
             dipivoxil or others drugs(aspirin, antibiotics etc)or has the significant past history
             of hypersensitivity reaction clinically

          -  The person who shows results of the 1.5 times upper limit in screening test of
             AST(SGOT), ALT(SGPT)

          -  The person who shows results of the positive HBsAg, HCV Ab,HIV Ab

          -  The person who has a past history of drug abuse or shows a positive result of drug
             abuse in urine drug analysis of screening test

          -  The person who takes medications of some medicine and medical supplies or oriental
             medicine within 2 weeks before the first administration date', or some OTC drug,
             vitamin supplements or health functional food within 1week (if only,it's confirmed by
             the investigator's judgment that they are not affected in pharmacokinetics character
             and safety evaluation about the clinical drugs)

          -  The person who participates in other clinical trials within 2 weeks before the first
             administration date'

          -  The person who donates plasma pheresis within 1 month before the first administration
             date, donates whole blood within 2 months before the first administration date or
             receives a transfusion within a month before the first administration date

          -  Persistent drinker(over 21 units/week, 1 unit = 10g of pure alcohol) or a drinker who
             can't stop drinking during hospitalization period

          -  Smoker who takes a drag over 10 cigarettes per day during the past three months

          -  The person who was judged unfit for participating in clinical trials by a investigator
             because of the clinical laboratory test results or other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>September 16, 2012</last_update_submitted>
  <last_update_submitted_qc>September 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clevudine and Adefovir dipivoxil</keyword>
  <keyword>pharmacokinetic drug drug interaction</keyword>
  <keyword>oral administration</keyword>
  <keyword>male subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

